Fasting Insulin: The Metabolic Marker You Are Missing
Fasting glucose rises years after insulin resistance begins. Insulin rises first, and it is rarely on a standard panel.
The Short Answer
Insulin resistance develops over years before fasting glucose moves, because the pancreas compensates by producing more insulin to hold glucose in range. By the time fasting glucose is abnormal, the compensation is failing and the process has been running for a long time. Fasting insulin captures the compensation itself, which makes it an earlier signal, and it is almost never included in a standard metabolic panel.
Why Glucose Is a Late Signal
The sequence in developing insulin resistance is well described. Tissue sensitivity falls, so the pancreas secretes more insulin to achieve the same glucose disposal. Glucose stays normal. Insulin is elevated. This state, compensated hyperinsulinaemia, can persist for years.
Only when beta cell output can no longer keep pace does fasting glucose rise, first into the impaired fasting glucose range and then further. HbA1c follows a similar late trajectory since it reflects average glycaemia.
The practical consequence is that a person can have substantial insulin resistance, elevated cardiovascular risk and progressing metabolic dysfunction with a completely normal fasting glucose and HbA1c. Reassurance from those two markers is reassurance about a later stage of the process.
This is why fasting insulin is worth ordering, and why metabolic health assessment built only on glucose measures is starting too late.
Interpreting the Value
There is no consensus optimal range, which is part of why the test is under-used, and reasonable practice reads it as a continuum.
Reference ranges are wide, commonly extending to around 25 microIU/mL, and the upper part of that range describes people with substantial insulin resistance. Many clinicians working in metabolic health regard values in the low single digits as favourable, with values above roughly 8 to 10 microIU/mL suggesting meaningful resistance, though these thresholds are practice-based rather than guideline-established.
HOMA-IR combines fasting insulin and fasting glucose into a single index, calculated as fasting insulin in microIU/mL multiplied by fasting glucose in mmol/L, divided by 22.5. It is a research-derived index and is widely used, with lower values indicating better sensitivity.
The triglyceride to HDL ratio is a free proxy computed from any standard lipid panel, and it correlates with insulin resistance well enough to be useful when insulin is not available. Ratios above roughly 2 using mg/dL units, or above about 0.9 using mmol/L, suggest resistance, with the caveat that the relationship differs across ethnic groups.
The Assay Caveats That Matter
| Issue | Consequence |
|---|---|
| Assay standardisation | Insulin assays are less standardised than glucose; values differ between laboratories |
| Biological variability | Substantial within-person variation; two measurements are better than one |
| Fasting state | Requires a genuine 8 to 12 hour fast; a small amount of food invalidates it |
| Recent exercise | Acute exercise improves insulin sensitivity for up to 48 hours, lowering the value |
| Acute illness and stress | Raise insulin resistance transiently |
| Exogenous insulin or insulin secretagogues | Make the measurement uninterpretable for this purpose |
| C-peptide as an alternative | Longer half-life, less pulsatile, useful where insulin is being administered |
The exercise point is the one most likely to mislead an individual. A single hard session in the 48 hours before a draw can lower fasting insulin meaningfully, which is a real physiological effect and not what you want to measure if you are looking for a stable baseline. Standardising to a similar activity state before each draw makes serial comparison interpretable.
What Moves It
Fasting insulin responds to intervention faster and more substantially than most markers, which is part of what makes it useful.
Exercise. Both aerobic and resistance training improve insulin sensitivity, with acute effects lasting up to 48 hours and chronic adaptation on top. Regular training is the single most reliable lever.
Visceral adiposity reduction. The largest effect where excess adiposity is present, since intramuscular and hepatic lipid accumulation drives resistance directly.
Sleep. A few nights of restriction measurably reduce insulin sensitivity in controlled studies, which makes sleep a metabolic intervention rather than an adjacent one.
Reducing refined carbohydrate and ultra-processed food intake, and avoiding chronic energy surplus.
Muscle mass. Skeletal muscle is the principal site of insulin-mediated glucose disposal, so preserving it supports sensitivity.
Where relevant clinically: several medication classes improve insulin sensitivity, and that is a clinical conversation rather than a supplement one.
Among supplements, berberine has the strongest human glycaemic data and behaves like a drug with a substantial interaction profile. Magnesium and inositol in PCOS have reasonable cases. Most of the rest have little.
When and How to Use It
Order it with the lipid panel, since the two are interpreted together and the triglyceride to HDL ratio comes free.
Fast properly, 8 to 12 hours, water only.
Avoid hard exercise for 48 hours before the draw if you want a stable baseline, and keep that condition consistent across measurements.
Repeat before acting, given assay and biological variability.
Interpret alongside HbA1c, triglycerides, HDL, waist circumference, blood pressure and liver enzymes. A raised fasting insulin with a raised triglyceride to HDL ratio, central adiposity and mildly raised liver enzymes is a coherent picture; an isolated raised insulin with everything else normal warrants confirmation first.
Re-measure at three to six months after an intervention. This marker moves in that window, which makes it one of the more satisfying to track.
Escalate clinically for: fasting glucose in the impaired range, HbA1c above the prediabetes threshold, symptoms of hyperglycaemia, or features suggesting a specific endocrine cause.
Why It Is Not on Standard Panels
The absence is not an oversight, it reflects how clinical guidelines are constructed.
Guidelines are built around decision thresholds with outcome evidence and defined management pathways. Diabetes is defined by glucose and HbA1c criteria, so those are what get measured. There is no established insulin threshold that triggers a specific licensed intervention, so there is no guideline reason to measure it in routine practice.
That is a defensible position for population screening and a limitation for anyone interested in the years before a threshold is crossed. The intervention for early insulin resistance, exercise, adiposity reduction, sleep and dietary change, does not require a licensed medicine, which is exactly why measuring it is useful to an individual and not to a guideline.
The practical implication: you will usually have to ask for it, and it will usually be worth asking for.
The AEONNN Perspective
Fasting insulin is one of the clearest cases where AEONNN's Evidence layer and the Consensus layer point in slightly different directions, and the platform states why rather than choosing silently. Guidelines are built around decision thresholds with licensed interventions attached, and there is no insulin threshold of that kind, so it stays off routine panels. For a member interested in the decade before a threshold, it is among the most informative measures available.
The Quality layer carries the caveats that decide whether a value means anything: insulin assays are less standardised than glucose, within-person variability is substantial, and a hard training session in the preceding 48 hours lowers the result through a genuine physiological effect. Standardising activity state before each draw is what makes serial comparison possible.
It maps to Pillar 4 and reaches Pillar 9 and Pillar 7, since sleep restriction reduces insulin sensitivity within days and skeletal muscle is the principal site of glucose disposal. It is also one of the faster-moving markers, which makes it well suited to the Insight Protocol's three-month observation window.
Pillar Matrix mapping
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
Why measure fasting insulin instead of glucose?
Insulin rises years before glucose, because the pancreas compensates to hold glucose in range. A normal fasting glucose and HbA1c can coexist with substantial insulin resistance.
What is a good fasting insulin level?
There is no guideline-established optimal range. Reference ranges extend well into resistance territory, and practice-based thresholds regard low single digits as favourable and above roughly 8 to 10 microIU/mL as suggesting resistance.
What is HOMA-IR?
An index combining fasting insulin and fasting glucose: insulin in microIU/mL multiplied by glucose in mmol/L, divided by 22.5. Lower values indicate better insulin sensitivity.
Is there a free alternative?
The triglyceride to HDL ratio, computed from any standard lipid panel, correlates with insulin resistance well enough to be useful, with variation across ethnic groups.
Does exercise before the test affect the result?
Yes. Acute exercise improves insulin sensitivity for up to 48 hours and lowers the value. Keeping activity state consistent before each draw makes serial comparison interpretable.
What lowers fasting insulin?
Exercise, reducing visceral adiposity, adequate sleep, less refined carbohydrate and ultra-processed food, and preserving muscle mass. It responds within three to six months.
Why is it not on standard panels?
Guidelines measure what has a decision threshold attached to a licensed intervention. There is no such insulin threshold, so it is not routine, which means you usually have to ask.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.